Microbot Medical Highlights LIBERTY Commercial Traction at Roth Conference

Microbot Medical ( (MBOT) ) has provided an announcement.

On March 17, 2026, Microbot Medical announced it will participate in the 38th Annual Roth Conference, held March 22-24, 2026, in Laguna Niguel, California, where CEO Harel Gadot will join a live fireside Q&A on March 23. The company is using the event and updated investor presentation materials to spotlight growing commercial traction from the limited market release of its LIBERTY system and to build investor awareness ahead of a planned full market launch at the Society of Interventional Radiology conference in April 2026.

Management emphasized that multi-site customer adoption and a diverse range of procedures during the limited rollout have reinforced its commercialization strategy and support expectations for a broader rollout. By leveraging the Roth platform for one-on-one meetings with growth-oriented institutional investors, Microbot aims to strengthen its market positioning in endovascular robotics and signal momentum in the early commercialization of LIBERTY, which addresses physician safety and staffing challenges in peripheral vascular care.

The most recent analyst rating on (MBOT) stock is a Buy with a $12.00 price target. To see the full list of analyst forecasts on Microbot Medical stock, see the MBOT Stock Forecast page.

More about Microbot Medical

Microbot Medical Inc. is a commercial-stage medical device company focused on transforming endovascular procedures through advanced robotic technology. Its flagship product, the LIBERTY Endovascular Robotic System, is the first FDA-cleared, single-use, remotely operated robotic solution designed to improve precision, efficiency and safety in peripheral endovascular interventions.

Average Trading Volume: 1,984,196

Technical Sentiment Signal: Buy

Current Market Cap: $183.3M

For detailed information about MBOT stock, go to TipRanks’ Stock Analysis page.